HER2neoadjuvantchemotherapy

由SKChia著作·被引用12次—Neoadjuvantchemotherapywithtrastuzumabfollowedbyadjuvanttrastuzumabversusneoadjuvantchemotherapyalone,inpatientswithHER2 ...,由ZJYang著作·2024—Neoadjuvantchemotherapywithdual-targetedtherapyisthestandardtreatmentforhumanepidermalgrowthfactor2(HER2)-positivebreast ...,由MTakada著作·2020·被引用62次—Severalstudieshaveshownthatneoadjuvantchemotherapywithtrastuzumabpluspertu...

參考資訊如下
Neoadjuvant and Adjuvant Therapy for HER2 Positive ...

由 SK Chia 著作 · 被引用 12 次 — Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2 ...

Real-world data on neoadjuvant chemotherapy with dual

由 ZJ Yang 著作 · 2024 — Neoadjuvant chemotherapy with dual-targeted therapy is the standard treatment for human epidermal growth factor 2 (HER2)-positive breast ...

Neoadjuvant treatment for HER2

由 M Takada 著作 · 2020 · 被引用 62 次 — Several studies have shown that neoadjuvant chemotherapy with trastuzumab plus pertuzumab is tolerable, increases the pCR rate compared with ...

Landscape of neoadjuvant therapy in HER2

由 G Villacampa 著作 · 被引用 4 次 — Dual HER2 blockade with chemotherapy is the recommended choice as neoadjuvant therapy for HER2-positive breast cancer, preferably by omitting ...

Neoadjuvant Therapies for Breast Cancer

For HER2-positive tumors, neoadjuvant therapy usually includes a combination of chemotherapy and the HER2-targeted therapy drugs trastuzumab (Herceptin) and ...

Review of the status of neoadjuvant therapy in HER2

Neoadjuvant chemotherapy with trastuzumab in HER2

由 IPC Buzatto 著作 · 2017 · 被引用 23 次 — Axillary pCR post neoadjuvant chemotherapy with trastuzumab was associated with reduced risk of recurrence (HR=0.34; P=0.03) and death (HR=0.21; P=0.02). In ...

Neoadjuvant and adjuvant treatment of patients with HER2 ...

由 N Harbeck 著作 · 2022 · 被引用 36 次 — Established neoadjuvant regimens in HER2+ EBC are either an anthracycline-taxane sequence plus HP or docetaxel-carboplatin plus dual HER2 blockade (TCbHP).

Neoadjuvant therapy for patients with HER2

2023年7月11日 — Cardiotoxicity of trastuzumab and other HER2-targeted agents · Choice of neoadjuvant chemotherapy for HER2-negative breast cancer · Clinical ...